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In eukaryotic cells, the rate-limiting component for cap-dependent mRNA translation is the translation initiation
factor eIF4E. eIF4E is overexpressed in a variety of human malignancies, but whether it has a role in melanoma
remains obscure. We hypothesized that eIF4E promotes melanoma cell proliferation and facilitates the
development of acquired resistance to the BRAF inhibitor vemurafenib. We show that eIF4E is overexpressed
in a panel of melanoma cell lines, compared with immortalized melanocytes. Knockdown of eIF4E significantly
repressed the proliferation of a subset of melanoma cell lines. Moreover, in BRAFV600E melanoma cell lines,
vemurafenib inhibits 4E-BP1 phosphorylation, thus promoting its binding to eIF4E. Cap-binding and polysome
profiling analysis confirmed that vemurafenib stabilizes the eIF4E–4E-BP1 association and blocks mRNA
translation, respectively. Conversely, in cells with acquired resistance to vemurafenib, there is an increased
dependence on eIF4E for survival; 4E-BP1 is highly phosphorylated and thus eIF4E-4E-BP1 associations are
impeded. Moreover, increasing eIF4E activity by silencing 4E-BP1/2 renders vemurafenib-responsive cells more
resistant to BRAF inhibition. In conclusion, these data suggest that therapeutically targeting eIF4E may be a viable
means of inhibiting melanoma cell proliferation and overcoming vemurafenib resistance.
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INTRODUCTION
Cutaneous melanoma is the most predominant form of skin
cancer, with approximately 50% of melanomas carrying
activating BRAF mutations (Bastian, 2014). The BRAFV600E
mutation leads to a 500-fold activation of BRAF and con-
stitutive activation of the mitogen-activated protein kinase
signaling pathway (Davies et al., 2002; Maurer et al., 2011).
In 2011, the US Food and Drug Administration approved
vemurafenib, a BRAF V600E inhibitor, for clinical use in
advanced melanoma (Young et al., 2012). Although patients
initially respond well, with pronounced tumor regressions
(Chapman et al., 2011) drug resistance almost inevitably
develops, with a median response duration of 6 months.
Multiple mechanisms involved in vemurafenib resistance have
been reported, including acquired EGFR upregulation (Sun
et al., 2014), mitogen-activated protein kinase signaling
pathway reactivation (Romano et al., 2013; Trunzer et al.,
2013), BRAF V600E and COT (MAP3K8) copy number gains
(Johannessen et al., 2010; Shi et al., 2012), BRAF V600E splice
variants (Poulikakos et al., 2011), as well as phosphatidylino-
sitol 30-kinase–AKT–mTOR (mammalian target of rapamycin)
activation (Greger et al., 2012).
One potential vemurafenib resistance mechanism that has
not been well defined in melanoma involves the eIF4F
complex, which consists of eIF4A, an RNA-dependent ATPase
and helicase, eIF4G1, a scaffolding protein that mediates
40S ribosomal bridging with eIF4F, and eIF4E, a m7GpppN
(N is any nucleotide) cap-dependent RNA-binding protein
(Topisirovic et al., 2011). eIF4E facilitates the translation
of pro-oncogenic mRNAs, such as vascular endothelial
growth factor, cyclin D3, and Mcl-1 (Topisirovic et al.,
2011). In vitro, overexpression of eIF4E is sufficient to
induce transformation (Lazaris-Karatzas et al., 1990; Avdulov
et al., 2004), whereas in vivo overexpression is associated
with prostate cancer and lymphoma (Ruggero et al., 2004;
Graff et al., 2009), among other cancers. Moreover, in human
breast cancer cells, blocking eIF4E decreases mRNA
translation and anchorage-independent growth (Soni et al.,
2008) and also inhibits cell proliferation (Pettersson et al.,
2011). Although eIF4E has been reported to be overexpressed
in various hematological malignancies and solid tumors
(Mamane et al., 2004), its role in melanoma remains largely
unknown.
The activity of eIF4E is regulated by its binding proteins and
upstream signaling pathways. Several eIF4E-binding proteins
have been documented in the literature, but the best char-
acterized are eIF4E-binding proteins (4E-BP) 1 and 2 (Pause
et al., 1994; Richter and Sonenberg, 2005). When 4E-BP1 is
ORIGINAL ARTICLE
1Experimental Medicine, Faculty of Medicine, McGill University, Montre´al,
QC, Canada and 2Segal Cancer Centre, Lady Davis Institute, Jewish General
Hospital, McGill University, Montre´al, QC, Canada
Correspondence: Wilson H. Miller Jr., Experimental Medicine, Faculty of
Medicine, McGill University, and Segal Cancer Centre, Lady Davis Institute,
Jewish General Hospital, Montreal, QC, Canada.
E-mail: wmiller@ldi.jgh.mcgill.ca
Received 8 August 2014; revised 4 January 2014; accepted 7 January 2015;
accepted article preview online 23 January 2015; published online 19
February 2015
1368 Journal of Investigative Dermatology (2015), Volume 135 & 2015 The Society for Investigative Dermatology
hypophosphorylated, it binds to eIF4E, inhibiting cap-
dependent translation (Gingras et al., 1998). Conversely,
when 4E-BP1 is hyperphosphorylated via activated mTOR,
eIF4E is liberated, allowing cap-dependent translation to
proceed (Lawrence and Abraham, 1997). Thus, the phospha-
tidylinositol 30-kinase /Akt/mTOR pathway activates eIF4E via
hyperphosphorylation of 4E-BP1. When this pathway is
constitutively activated, the eIF4E-mRNA complex forms and
cap-dependent translation is active, which leads to continuous
cell proliferation (Boussemart et al., 2014).
In this report, we characterize the role of eIF4E and its
binding partners in a panel of melanoma cell lines. Impor-
tantly, we provide evidence that melanoma cells can escape
the effects of vemurafenib by a mechanism involving
increased phosphorylation of 4E-BP1 and bioavailability of
eIF4E. Our findings provide the groundwork for novel combi-
natorial therapeutic approaches targeting BRAF V600E and
eIF4E in melanoma.
RESULTS
Melanomas with elevated phospho-4E-BP1 and phospho-AKT
protein levels are more sensitive to eIF4E knockdown
To determine the role of eIF4E in melanoma, we first analyzed
the expression of eIF4E and eIF4G1, components of the eIF4F
complex, within a panel of melanoma cell lines, versus
immortalized melanocytes, MelST (Gupta et al., 2005). As
shown in Figure 1a, various melanoma cell lines, expressing
either wild-type or mutant BRAF, expressed high levels of
eIF4E compared with immortalized MelST melanocytes. We
also analyzed the eIF4F complex scaffolding protein, eIF4G1,
and found that its expression varied across cell lines
(Supplementary Figure S1a online), as did the expression of
4E-BP1 (Figure 1a). Interestingly, profiling of the phosphoryla-
tion status of extracellular signal–regulated kinase (ERK) and
AKT in the panel of melanoma cells revealed a striking
correlation between 4E-BP1 hyperphosphorylation and phos-
pho-AKT (Figure 1b). Increased phospho-4E-BP1 suggests that
the bioavailabilty of eIF4E is increased in a subset of
melanoma cell lines, as the phosphorylated form of 4E-BP1
fails to bind and repress eIF4E.
We then investigated whether eIF4E is a regulator of cell
proliferation in a subset of melanoma cells. Following eIF4E
knockdown via small interfering RNA (siRNA), we found that
four lines were highly sensitive to eIF4E silencing: A375M,
MM117, MM102, and MM111 (Figure 1c, Supplementary
Figure S1b and d online). Although BLM and SKMel28
exhibited intermediate responsiveness, the remaining cell lines
(WM164, MM57, 451Lu, and A375) continued to proliferate
in comparison with control siRNA (siCTL), despite eIF4E
knockdown (Figure 1c, Supplementary Figure S1b online).
Interestingly, the cell lines with the greatest cell proliferation
inhibition upon eIF4E silencing expressed the highest levels of
phospho-AKT and phospho-4E-BP1 (Figure 1b–d, Supplemen-
tary Figure S1c online), suggesting that cells with increased
eIF4E activity were more dependent on this pathway for
survival. All 10 cell lines examined had a similar efficiency
of eIF4E depletion; thus, the differences in proliferation follow-
ing eIF4E knockdown were not simply due to differential
silencing of eIF4E in one cell line versus another (Figure 3a
and Supplementary Figure S1d online).
Vemurafenib reduces the phosphorylation of the eIF4E inhibitory
protein 4E-BP1 in BRAFV600E mutant lines
Having demonstrated that silencing eIF4E can block the
proliferation of some but not all melanoma cell lines exam-
ined, we next wanted to determine whether vemurafenib had
any effect on the eIF4F complex. We assessed the phosphor-
ylation of 4E-BP1 after treatment with vemurafenib in three
BRAFV600E mutant melanoma cell lines: A375, SKMel28, and
A375M. In all three cell lines, we observed a time-dependent
decrease in the phosphorylation of 4E-BP1 using a phospho-
specific 4E-BP1 antibody and by detecting a reduction in the
hyperphosphorylated, slower migrating forms of 4E-BP1
following vemurafenib treatment (Figure 2a). Furthermore, as
shown in Figure 2a, there is a marked decrease in ERK
activation (phospho-ERK) upon 4-hour vemurafinib treatment,
demonstrating an early inhibitory role of vemurafenib on the
mitogen-activated protein kinase pathway. We next assessed
the levels of phospho-p70S6K and phospho-S6, which lie
downstream of mTOR. Consistent with previously published
data, we found that the phosphorylation of S6 was decreased
by vemurafenib treatment (Figure 2b) (Atefi et al., 2011;
Corcoran et al., 2013). No consistent changes in AKT
and P70S6K activation (phospho-AKT and phospho-P70S6K)
were detected in these cell lines treated with vemurafenib
(Figure 2b).
To further explore the effect of vemurafenib on the eIF4E/
4E-BP1 association, we performed cap-binding assays using
7-methyl-GTP-bound agarose beads (Figure 2c). In this assay,
eIF4E present in cell lysates binds to cap-mimicking beads,
also enabling proteins bound to eIF4E to be assessed upon
elution (Sonenberg et al., 1979). In vemurafenib-treated cells,
we observed increased binding between eIF4E and 4E-BP1,
which occurs when 4E-BP1 is dephosphorylated, leading to
decreased cap-dependent translation. Of note, PP242, an
mTORC1/2 inhibitor, was used as a positive control, leading
to 4E-BP1 hypophosphorylation and increased eIF4E:4E-BP1
association (Figure 2a and c).
Dephosphorylation of 4E-BP1 and subsequent eIF4E:4E-BP1
complex formation typically corresponds to an inhibition of
translation initiation. To further investigate this, we assessed
the effect of vemurafenib on the polysome distribution in
BRAFV600E mutant melanoma cells. Treatment of A375 cells
with vemurafenib for 4 hours did not result in an inhibition of
translation (data not shown). However, after 24 hours, there
was a decrease in the abundance of polysomes (Figure 2d),
consistent with a block in eIF4F complex formation. Western
blotting analysis showed that the expression of the eIF4E
translational targets vascular endothelial growth factor, cyclin
D3, c-Myc, and Bcl-2 expression was drastically repressed by
vemurafenib treatment (Figure 2d). Cyclin D3 is a well-
characterized eIF4E-sensitive mRNA (Dowling et al., 2010;
Alain et al., 2012). In keeping with our results that
vemurafenib can block mRNA translation, we observed a
shift in the polysome loading, from heavy to light polysomes,
of cyclin D3 mRNAs in A375 cells treated with vemurafenib
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(Figure 2e, Supplementary Figure S2 online). Moreover,
vemurafenib had no impact on the polysome loading of two
eIF4E-insensitive mRNAs: glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) and b-actin (Figure 2e and Supplemen-
tary Figure S2 online). These data suggest that vemurafenib-
induced reduction in cell proliferation is associated with
defects in eIF4E-mediated translation initiation.
eIF4E contributes to vemurafenib resistance in A375 BRAFV600E
melanomas
Having demonstrated that vemurafenib functions in part by
repressing 4E-BP1 phosphorylation and increasing eIF4E:4E-
BP complex formation, we next examined the status of
the eIF4F complex in cells with acquired resistance to
vemurafenib. Here, we obtained the parental BRAFV600E
mutant human melanoma cell line, A375, and corresponding
vemurafenib-resistant cell lines, denoted A375(A)R1 and AR2
(Su et al., 2012). To ensure that AR1 and AR2 cell lines were
valid models of acquired resistance, and not merely
chronically adapted to vemurafenib, we maintained the AR1
and AR2 cell lines in the absence of vemurafenib for 1 month
and referred to these as AR1 and AR2 wash-off (WO) cell
lines, AR1WO and AR2WO, respectively. We next challenged
AR1WO and AR2WO cells with vemurafenib, and, as shown
in Supplementary Figure S3a online, withdrawal of vemurafe-
nib from the media for 1 month does not cause AR1 and AR2
cell lines to regain sensitivity to vemurafenib. Next, to
determine whether eIF4E activity is associated with acquired
resistance to vemurafenib, we performed eIF4E knockdown in
both parental and resistant lines, with or without vemurafenib,
and confirmed the efficiency of silencing by western blotting
(Figure 3a). The proliferation of AR1 and AR2 is significantly
inhibited by eIF4E silencing, compared with their parental
counterpart (Figure 3a). Furthermore, evidence supporting a
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Figure 1. eIF4E knockdown inhibits proliferation in melanoma cell lines that highly express eIF4E, p-AKT, and hyperphosphorylated 4E-BP1. (a) Western
blottings displaying eIF4E and 4E-BP1 protein expression in a panel of melanoma cell lines compared with immortalized melanocytes (MelST). Underlined are the
cell lines that possess a BRAF V600E mutation. The schematic (right) shows the relationship between the phosphorylation status of 4E-BP and its ability to bind and
inhibit eIF4E. (b) Western blotting of p-AKT, AKT, phospho-extracellular signal–regulated kinase (p-ERK), ERK2, and p-4E-BP1 in melanoma cell lines versus
immortalized melanocytes (MelST). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a loading control in all immunoblots. Four bands can be seen on the
p-4E-BP1 blot: the upper band represents the hyperphosphorylated form, whereas the lower band represents the hypophosphorylated form. The lowest band
identified with an asterisk shows the phosphorylation of 4E-BP2. Correlation between the expression of p-AKT and p-4E-BP1 in the melanoma cell lines is shown
(right). Pearson’s correlation statistics have been used. (c) Cell proliferation assay plot following 4-day eIF4E siRNA treatment, assessed by sulforhodamine B (SRB)
staining. Error bars are defined as mean±SD, n¼ 3. (d) Correlation between the levels of proliferation inhibition upon eIF4E siRNA silencing versus p-4E-BP1
expression. Pearson’s correlation statistics have been used. Note: p-4E-BP1 and p-AKT protein levels were normalized to corresponding GAPDH levels.
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role of vemurafenib working via suppression of eIF4E activity
is demonstrated by data (e.g., AR1WO vs. AR1þV) showing
that the addition of the BRAF inhibitor does not potentiate the
effect of eIF4E silencing in the resistant cell lines (Figure 3a).
Silencing of eIF4E can inhibit the proliferation of vemur-
afenib-resistant cells. We investigated the integrity of the eIF4F
complex in order to provide mechanistic insight toward
this observation. Cap-binding analysis demonstrated that,
compared with the parental A375, vemurafenib-resistant
lines AR1, AR2, AR1WO, and AR2WO cell lines exhibited
decreased eIF4E:4E-BP1 complex formation, leading to
increased eIF4E:eIF4G1 association (Figure 3b). Furthermore,
compared with the parental A375 cell line, vemurafenib-
resistant lines overexpressed cyclin D3 and vascular endothe-
lial growth factor, two well-documented eIF4E downstream
targets (Dowling et al., 2010; Topisirovic et al., 2011).
(Figure 3c). Our results suggest an increased role of eIF4E in
the survival of cells with acquired resistance to vemurafenib.
4E-BP1/2 stable knockdown contributes to vemurafenib
resistance in A375 cells
The data we have shown support the hypothesis that acquired
resistance to vemurafenib is facilitated by hyperphosphoryla-
tion of 4E-BP1, leading to increased cap-dependent mRNA
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translation, relative to parental A375. To further investigate the
role of 4E-BP1 in resistance to vemurafenib, we transduced
cells with retroviral particles expressing sh4E-BP1 and sh4E-
BP2 RNAs. Knockdown of 4E-BP1/2 would have a similar
effect on eIF4E activity as a 4E-BP1/2 hyperphosphorylation.
Following puromycin selection and immunoblot confirmation,
positive 4E-BP1/2 stable knockdown clones were established
(Figure 4a). Consistent with increased eIF4E activity, the
4E-BP1/2 double knockdown cell line expressed elevated
levels of eIF4E downstream targets c-Myc compared with
the control scrambled knockdown (shCTL) cell line
(Figure 4a). To determine the sensitivity to vemurafenib in
the 4E-BP1/2 knockdown cell line, we assessed cell prolifera-
tion. While the proliferation rates between A375 shCTL and
A375 shBP1/2 cell lines were similar, the 4E-BP1/2 double
knockdown cells were more resistant to vemurafenib com-
pared with their control knockdown counterparts (Figure 4b).
Furthermore, in long-term clonogenic (proliferation) assays,
we showed that the A375 shBP1/2 cell line is more resistant to
vemurafenib compared with the A375 shCTL cell line
(Figure 4c). To summarize, these data demonstrate that
depletion of 4E-BP1/2 can cause a partial rescue of vemur-
afenib-induced inhibition of proliferation.
DISCUSSION
Gain-of-function BRAF mutations are common in melanoma,
and although patients with tumors harboring mutant BRAF
initially respond to targeted agents, resistance develops in
most cases (Wiesner et al., 2012; Zebary et al., 2013;
Boussemart et al., 2014). Significant efforts have been made
to understand the sensitivity and resistance to vemurafenib in
this context, with several investigations focusing on the ERK
and phosphatidylinositol 30-kinase –Akt/mTOR pathways in
melanoma progression (Nazarian et al., 2010; Villanueva
et al., 2010). Interestingly, the profiles of downstream
events, such as MNK phosphorylation (directly upstream of
eIF4E) and, specifically, eIF4E expression, remain poorly
documented in melanoma.
We found that a subset of cell lines expressed high levels of
phospho-Akt, which correlated with elevated expression of
hyperphosphorylated 4E-BP1 (Figure 1b). This led us to reason
that the survival of this subset of melanoma cells (A375M,
MM117, MM102, MM111, BLM, and SKMel28) would be
driven by less sequestered, and more bioavailable, eIF4E
(Pause et al., 1994). The proliferation of these cell lines was
significantly decreased when eIF4E was silenced, suggesting
that this translation factor helps drive melanoma progression
(Figure 1c, Supplementary Figure S1b online). Our data
show that treatment of A375 cells with vemurafenib causes
(1) a time-dependent reduction in the phosphorylation of
4E-BP1 (Figures 2a), (2) increased eIF4E:4E-BP1 association
(Figure 2c), and (3) decreased abundance of light and heavy
polysome fractions, as well as the reduced loading of eIF4E-
sensitive mRNA cyclin D3 in heavy polysomes (Figure 2d and
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e, and Supplementary Figure S2 online); these results point to
a role of vemurafenib in inhibiting eIF4E-mediated mRNA
translation.
Conversely, in terms of resistance to chemotherapeutics,
overexpression of eIF4E has been documented following
anthracycline treatment in breast cancer (Heikkinen et al.,
2013), rapamycin treatment in murine lymphoma models
(Wendel et al., 2004, 2006), and, here, upon vemurafenib
resistance in melanoma. Significant work by other groups has
been put forward to address chemotherapy resistance in
melanoma cells. Specifically, the observance of elevated
phospho-4E-BP1 has been documented in cross-resistance to
BRAF or mitogen-activated protein kinase/ERK kinase (MEK)
inhibitors, which could be overcome by treating resistant cells
with the mTOR inhibitor rapamycin (Atefi et al., 2011).
Furthermore, the use of second-generation mTOR inhibitors,
such as everolimus and temsirolimus, alongside vemurafenib
has come to fruition in clinical trials (see NCT01596140).
Although targeting mTOR in such cases has the potential to
regress and/or eradicate tumors, this may be insufficient, as
elevated phospho-4E-BP1 levels are often associated with
relatively high levels of eIF4E. Thus examining the eIF4E/4E-
BP ratio upon administration of mTOR inhibitors (Alain et al.,
2012), or perhaps, more effectively, directly targeting eIF4E
should provide a more pronounced effect clinically.
During preparation of this paper, a mechanism of resistance
to anti-BRAF and anti-MEK treatment of melanomas was
shown to involve heightened activation of the eIF4F complex
(Boussemart et al., 2014). As a means of targeting the eIF4F
complex in response to standards of care, flavagline
derivatives were developed, and were shown to depress
translation of exogenous 50-capped mRNA and reduce tumor
volume in a Mel624 xenograft model (in concert with anti-
BRAF). Although this investigation is promising in terms of
targeting eIF4A, further examination of the effect of flavaglines
on known eIF4E translational targets (e.g., c-Myc, cyclin D3)
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Figure 4. Stable knockdown of 4E-BP1/2 contributes to the development of vemurafenib resistance in A375 cells. (a) Western blotting of c-Myc, 4E-BP1, 4E-BP2,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; loading control) in A375 shCTL and shBP1/2 cell lines. (b) Cell proliferation assay after 4 days with or
without 0.5mM vemurafenib treatment in A375 shCTL and shBP1/2 stable cell lines. Error bars are defined as mean±SD, n¼3. Statistical significance was
determined by one-way analysis of variance followed by the Newman–Keuls post-hoc test using Prism version 3.0 (GraphPad Software, San Diego, CA).
(c) Clonogenic assay after 14 days with or without 0.5mM vemurafenib treatment in A375 shCTL and shBP1/2 stable cell lines. The number of colonies was counted
manually and graphed. Error bars are defined as mean±SD, n¼3. Statistical significance was determined by one-way analysis of variance followed by the
Newman–Keuls post-hoc test using Prism version 3.0 (GraphPad Software). *Po0.05, **Po0.01. Representative pictures are shown on the right. NS, not significant.
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and their effect on multiple melanoma cell lines and xenograft
models would add to this approach.
In our study of genetically blocking eIF4E, rather than
chemical inhibition of eIF4A with flavaglines (Basmadjian
et al., 2013), we observed the most pronounced inhibition of
proliferation in cell lines with elevated phospho-4E-BP1 levels
(Figure 1d). Exploring the effect of flavaglines within our panel
of cell lines, in terms of proliferation inhibition and eIF4E
target expression, would further support the clinical delivery of
flavaglines in concert with anti-MEK and anti-BRAF therapies.
Overall, our data demonstrate that eIF4E promotes mela-
noma cell proliferation and may have a role in developing
acquired resistance to the BRAF V600E inhibitor vemurafenib.
Thus, targeting eIF4E in melanoma may be a novel therapeutic
option geared toward cells expressing high basal levels of
phospho-4E-BP1 and/or eIF4E upon acquired resistance to
vemurafenib. Moreover, we hypothesize that eIF4E may
promote vemurafenib resistance by promoting translation
initiation of specific mRNAs, such as those intimately linked
to cell survival. The literature supports this hypothesis, show-
ing that proliferation and pro-survival mRNAs are less effi-
ciently translated when cap-dependent (eIF4E-mediated)
translation is blocked (Larsson et al., 2007; Hsieh et al.,
2012). Future work in our lab will also focus on isolating
translating ribosomes (polysomes) to define specific mRNAs,
whereby translation is dependent on activated eIF4E in cells
with acquired resistance to vemurafenib. Identification of
specific mRNAs that are essential for eIF4E-mediated
resistance to vemurafenib may suggest novel therapies, in
addition to eIF4E inhibitors, to prevent or overcome resistance.
The work presented herein supports the importance of
validating phospho-4E-BP1 and eIF4E as markers of resistance
to BRAF inhibitors, using patient-derived prerelapse and
postrelapse melanoma samples. We anticipate that a combi-
natorial drug treatment approach involving vemurafenib and
novel eIF4E-targeting therapies will significantly reduce mel-
anoma progression.
MATERIALS AND METHODS
Reagents
Vemurafenib was obtained from Plexxikon (Berkeley, CA), and PP242
was purchased at Sigma Aldrich (St. Louis, MO). All drugs were
dissolved in DMSO to 10 mM, and aliquots were stored at  80 1C.
Antibodies eIF4G1, 4E-BP1, phospho-4E-BP1 (p-4E-BP1; T37/46),
phospho-eIF4E (p-eIF4E; Ser209), phospho-ERK (p-ERK; T202/Y204),
4E-BP2, c-Myc, phospho-AKT (p-AKT; Ser 473) AKT, cyclin D3,
phospho-S6 (p-S6; S240/244), S6, phospho-P70S6K (p-P70S6K; Thr
389), P70S6K, and GAPDH were purchased from Cell Signalling
Technology (Danvers, MA). The eIF4E antibody was purchased from
BD Biosciences (Mississauga, CA). Immobilized r-Aminophenyl-
m7GTP agarose beads were purchased from Jena Science (Jena,
Germany). Transfection reagents Lipofectamine 2000 or Lipofecta-
mine RNAiMax were purchased from Invitrogen (Burlington, CA).
Cell culture
All cell lines used in this paper, except A375 and vemurafenib-
resistant lines R1 and R2, were kindly provided by Dr Ghanem
Ghanem (Institut Jules Bordet, Bruxelles, Belgium). The A375M cell
line is a metastatic derivative of the A375 cell line originally reported
by Dr JM Kozlowski (Kozlowski et al., 1984). A375M, BLM, SkMel28,
A375, and MelST were maintained in monolayer culture in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS)
and 1% Penicillin/Streptomycin; MM117, MM111, MM102, WM164,
MM57, 451Lu, and MM94 were cultured in HAM’s F10 with 10%
FBS and 1% Penicillin/Streptomycin. Vemurafenib-resistant cell lines
AR1 and AR2 were maintained in 2.5mM vemurafenib in DMEM with
10% FBS and 1% Penicillin/Streptomycin. For vemurafenib WO cell
lines termed AR1WO and AR2WO, AR1 and AR2 cells, were main-
tained in DMEM with 10% FBS and 1% Penicillin/Streptomycin for 1
month in the absence of vemurafenib. All cell lines were maintained
at 37 1C in a humidified incubator in 5% CO2.
Proliferation assay
Cell proliferation was tested by sulforhodamine B assay. Cells were
seeded on a 96-well plate the day before treatment. Cells were then
treated with vemurafenib for 24, 48, or 96 hours. For each time point,
96-well plates were harvested and fixed with 10% trichloroacetic
acid for 1 hour. Plates were then washed and sterilized with water
three times and allowed to air-dry overnight. Once the fixation was
completed, plates were stained with 0.4% (w/v) sulforhodamine B
100ml per well in 1% acetic acid for at least 30 minutes. After
staining, plates were washed with 1% acetic acid three times and air-
dried overnight. Bound sulforhodamine B was solubilized by adding
100ml per well of 10 mM unbuffered Tris base, pH 10.5, for
10 minutes. Absorbance at 564 nm was read using FLUOstar OPTIMA
plate reader.
Plasmids, virus production, stable cell selection
Human sh4E-BP1 and sh4E-BP2 vectors were purchased from Sigma
Aldrich (MISSION shRNAs). shRNAs were co-transfected with three
Lentivirus packaging constructs, PLP1, VSVG, and PLP2, into 293FT
cells using Lipofectamine 2000 (Invitrogen). Viral supernatants were
harvested 48-hours posttransfection and spun at 1,000 r.p.m. for
5 minutes. For establishing shBP1þBP2 stable knockdown cell lines,
control or shBP1/2 viral supernatants were added to 10-cm dishes
with adhered A375 cells for overnight infection. After two rounds of
infection, cells were treated with puromycin (1mg ml 1) for 48 hours,
and positive subclones were maintained.
Polysome profiling
Polysome profiling was performed as previously described by Gandin
et al. (2014). For sucrose gradient fractionation and polysome
isolation, A375 cells were seeded in 15-cm dishes with or without
2.5mM vemurafenib for 24 hours. Cells were treated with cyclo-
heximide (100mg ml 1) 5 minutes prior to harvesting, washed in
cold PBS containing 100mg ml 1 cycloheximide, and then spun for
5 minutes at 1,500 r.p.m. Cell pellets were lysed in hypotonic buffer
(5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 mM KCl, and 1 pro-
tease inhibitor cocktail (EDTA-free), containing 1 mM dithiothreitol
and RNAse inhibitor (100 units)). Samples were kept on ice for
12 minutes and then centrifuged at 13,000 r.p.m. for 8 minutes. The
supernatants were harvested and added to 10–50% sucrose gradient.
Gradients were centrifuged at 35,000 r.p.m. for 2 hours at 4 1C.
Fractions were collected (24 fractions, 12 drops each) using a Foxy
JR ISCO collector (Lincoln, NE), and data (absorbance, 254 nm) were
collected.
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Western blotting analysis
Cells were treated with vemurafenib (2.5mM) or PP242 (1mM) at the
indicated times, and pellets were harvested to obtain protein extracts.
Briefly, cell pellets were lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0,
with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate). After
sonication, cell lysates were centrifuged at 13,000 r.p.m. for 15 min-
utes. The supernatants were collected and protein concentrations
were quantified. Equal amounts of protein were loaded on 10% SDS-
PAGE. After transferring to a nitrocellulose membrane (Bio-Rad,
Mississauga, CA), 5% milk/TBS was used to block for 1 hour and
then probed for target antibodies overnight at 4 1C. After incubation
with horseradish peroxidase-conjugated secondary antibodies for
1 hour at room temperature, the signals of targeted protein were
developed with chemiluminescence substrate (Amersham, GE
Healthcare, Buckinghamshire, UK).
RNA interference
Cells were seeded in 10-cm dishes at 80% confluency. eIF4E siRNA or
control siRNA was added to the dishes after 20 minutes of incubation
with transfection reagent Lipofectamine RNAiMAX following the
manufacturer’s instructions. After 16 hours, cells were washed with
1 PBS, and fresh medium was added. At day 4 of transfection, cell
pellets were harvested for western blotting. The sequences of the
previously validated eIF4E siRNA pair were as follows: 50-AGAGUG-
GACUGCAUUUAAAUUUGdAdT-30 and 50-AUCAAAUUUAAAUG-
CAGUCCACUCUGC-30 (Pettersson et al., 2011). AllStars Negative
Control siRNA (Qiagen, Germantown, MD) was used as non-silencing
control.
m7GTP pull-down assay
Cells were treated with vemurafenib (2.5mM) or PP242 (1mM) at the
indicated times, and whole cell lysate was harvested. For eIF4E
pull-down assay, 20ml m7GTP agarose beads were added to each
tube and washed with IP buffer (Tris-HCl pH 7.5 50 mM, NaCl 150 mM,
EDTA 1 mM, EGTA 1 mM, TritonX-100 1%, and NP-40 0.5%) three
times. Quantified protein extracts were then added on top of the
m7GTP agarose beads at equal amounts in each tube and were
incubated with beads on the rotator overnight at 4 1C. Western blotting
was performed to determine the association between eIF4E and 4E-BP1
or eIF4G1.
RNA isolation
To isolate mRNAs in each polysome fractions, Trizol (Invitrogen)
was added into each fraction tube. After 5-minute incubation at
room temperature, 200ml of chloroform was added into each tube
and mixed well for 15 seconds. Following centrifugation at 12,000g
for 15 minutes at 4 1C, the clear phase was carefully obtained
and placed into a clean tube. A volume of 500ml of isopropanol
was added to the clear phase, and this mixture was centrifuged for
30 minutes (12,000g, 4 1C). The isopropanol was then removed,
and the remaining pellets were washed with 1 ml of 75% ethanol
(in diethylpyrocarbonate water) and centrifuged for 5 minutes
(12,000g, 4 1C). The liquid was then carefully removed, and the
pellets were allowed to air-dry. A volume of 20ml of diethy-
lpyrocarbonate water was added to dissolve the RNA pellets,
which were then quantitated (Thermo scientific Nanodrop 1000,
Wilmington, DE).
Semiquantitative reverse transcription PCR (sqRT-PCR) and
real-time qRT-PCR
Before performing the reverse transcription, 0.3mg of mRNA was
visualized by ethidium bromide agarose gel (2%) to check the quality
of mRNAs (integrity of 28 S and 18 S bands). For cDNA production, a
one-step RT-PCR kit (Bio-Rad) was used following the manufacturer’s
instructions. The sequences of human cyclin D3, GAPDH, and
b-actin primers were as follows: cyclin D3 forward 50-CTGGATCGC
TACCTGTCTTG-30, cyclin D3 reverse 50-TCCCACTTGAGCTTCCC
TAG-30; GAPDH forward 50-AATCCCATCACCATCTTCCA-30,
GAPDH reverse 50-TGAGTCCTTCCACGATACCA -30; and b-actin
forward 50-ACCACACCTTCTACAATGAGC-30, b-actin reverse
50-GATAGCACAGCCTGGATAGC-30. To perform sqRT-PCR, the
Taq DNA Polymerase Kit (Invitrogen) was used. For each of the
transcripts (cyclin D3, GAPDH, b-actin), two cycle numbers (25 and
35 cycles) were performed to make sure the PCR results were in the
linear range. Furthermore, cDNA was amplified for cyclin D3,
GAPDH, and b-actin by real-time PCR analysis (ABI Prism7500;
Applied Biosystems, Life Technologies, Burlington, CA) using SYBR
green technology according to the manufacturer’s instructions.
Clonogenic assay
A total of 300 cells per well were seeded in sixwell plates the day
before treatment. After overnight incubation, the attached cells were
treated with DMSO or vemurafenib at the indicated concentration, in
triplicate. After 14 days, the incubating medium was removed, and
the cells were stained with 0.5% (W/V) crystal violet in 70% ethanol.
After 1 hour of incubation at room temperature, staining dye was
washed, and the number of colonies was determined manually.
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